OCU-410ST is under clinical development by Ocugen and currently in Phase II for Juvenile Macular Degeneration (Stargardt Disease). According to GlobalData, Phase II drugs for Juvenile Macular Degeneration (Stargardt Disease) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the OCU-410ST LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OCU-410ST overview
OCU-410ST is under the development for the treatment of Stargardt disease, retinitis pigmentosa (RP19) and cone-rod dystrophy 3 (CORD3) diseases. The therapeutic candidate comprises of adeno-associated virus (AAV) vector delivering an RAR-related orphan receptor A (RORA) gene. It is developed based on modified gene therapy platform. It is administered as sub retinal injection. It is being developed based on AAV delivery platform.
Ocugen overview
Ocugen is a biopharmaceutical company that discovers, develops and commercializes and vaccines for improvement health for the treatment of eyes. The company’s pipeline products include OCU-400 for the treatment of NR2E3, RHO, CEP290, and PDE6B mutation associated retinal degeneration; OCU-410 targets dry age-related macular degeneration; OCU410ST treats targardt orphan disease; OCU200 for diabetic macular edema, diabetic retinopathy, wet-age related macular degeneration; NEOCART treats articular cartilage defects in the knee, OCU500 targets covid 19; OCU510 for flu; OCU520 is for the treatment of flu and covid 19. It utilizes a modified gene therapy platform to develop its products. The company operates in Ireland and the US. Ocugen is headquartered in Malvern, Pennsylvania, the US.
For a complete picture of OCU-410ST’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
